Introducing CAR-Mediated Nanovesicle Delivery: Advancing Precision Medicine

​

At Caravan Biologix, our focus is on leveraging the mini-CAR BioNV technology to address critical human diseases. Our platform provides a versatile foundation for developing various mini-CAR BioNVs tailored to treat different human diseases, demonstrating our dedication to advancing healthcare on multiple fronts.

​

A key aspect of our strategy involves collaborating with other biotech companies, offering our platform for the development of their mini-CAR BioNV-driven pipelines. The outsourcing of our platform technology can result in the production of standalone therapies or co-therapeutics alongside their existing medicines, showcasing our commitment to advancing healthcare through strategic partnerships and collaborations.

​

In addition to licensing, we are actively utilizing the mini-CAR BioNV platform to develop our own therapeutic pipeline, meticulously designed to enhance human health and showcase the platform's full range of properties, particularly its apoptotic protein and gene editor delivery capabilities. This strategic approach ensures that our research not only benefits our own pipeline but also contributes to the broader understanding and utilization of mini-CAR BioNV technology in the medical field.

​

Our apoptotic protein delivery capability pipeline is designed to target specific diseases with precision and efficacy. We are currently focused on delivering perforins and granzymes to expanded clonal B-cell populations in systemic lupus erythematosus (SLE), aiming to address the underlying causes of the disease. Additionally, our approach involves delivering wild type perforins to Natural Killer cells, restoring their immunomodulatory function and preventing certain types of Hemophagocytic Lymphohistiocytosis (HLH). In the realm of cancer therapy, we are working on delivering perforins, granzymes, and p53 to solid tumor cancers, offering a more effective alternative to whole-cell-based treatments.